We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Expands its Heart Drug Lineup with $13 billion MyoKardia Purchase
BMS Expands its Heart Drug Lineup with $13 billion MyoKardia Purchase
The deal gives BMS mavacamten, MyoKardia’s investigational treatment for obstructive hypertrophic cardiomyopathy, a chronic heart disease afflicting up to 200,000 individuals in the U.S. and the EU.